Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure

IJC Metabolic and Endocrine

Volumn 6, Issue , 2015, Pages 5-12

  Berry, Matthieu ^a,b   Galinier, Michel ^a,b   Delmas, Clement ^a,b   Fournier, Pauline ^a,b   Desmoulin, Franck ^a   Turkieh, Annie ^a   Mischak, Harald ^c   Mullen, William ^c   Barutaut, Manon ^a   Eurlings, Luc W ^d   Van Wijk, Sandra ^d   Brunner La Rocca, Hans Peter ^d   Caubere, Celine ^a   Butler, Javed ^e   Roncalli, Jérôme ^b   Evaristi, Maria Francesca ^a   Cohen Solal, Alain ^f   Seronde, Marie France ^f   Escamilla, Roger ^b   Ferrières, Jean ^b   Koukoui, François ^a   Smih, Fatima ^a   Rouet, Philippe ^a   more..

^a INSERM   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f APHP   (France)

Author keywords

Biomarkers; Diagnosis; Heart failure; Proteomics

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEART FAILURE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; TRANSTHORACIC ECHOCARDIOGRAPHY; URINALYSIS; VALIDATION PROCESS; WESTERN BLOTTING;

EID: 84926029953     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2014.11.003     Document Type: Article

References (31)

1. Kenchaiah S., Narula J., Vasan R.S. Risk factors for heart failure. Med Clin North Am 2004, 88:1145-1172.
2. Maisel A.S., Choudhary R. Biomarkers in acute heart failure-state of the art. Nat Rev Cardiol 2012, 9:478-490.
3. Ray P., Birolleau S., Riou B. Acute dyspnoea in elderly patients. Rev Mal Respir 2004, 21. 8S42-54.
4. Maeder M., Fehr T., Rickli H., Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006, 129:1349-1366.
5. Knudsen C.W., Clopton P., Westheim A., Klemsdal T.O., Wu A.H., Duc P., et al. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. Ann Emerg Med 2005, 45:573-580.
6. Knudsen C.W., Omland T., Clopton P., Westheim A., Wu A.H., Duc P., et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005, 46:838-844.
7. Mueller C., Scholer A., Laule-Kilian K., Martina B., Schindler C., Buser P., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654.
8. Ng L.L., Geeranavar S., Jennings S.C., Loke I., O'Brien R.J. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond) 2004, 106:129-133.
9. Ng L.L., Loke I.W., Davies J.E., Geeranavar S., Khunti K., Stone M.A., et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005, 45:1043-1050.
10. Smih F., Desmoulin F., Berry M., Turkieh A., Harmancey R., Iacovoni J., et al. Blood signature of pre-heart failure: a microarrays study. PLoS One 2011, 6:e20414.
11. Good D.M., Zurbig P., Argiles A., Bauer H.W., Behrens G., Coon J.J., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9:2424-2437.
12. Mischak H., Vlahou A., Ioannidis J.P. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 2013, 46:432-443.
13. DeLong E., DeLong D., Clarke-Pearson D. Comparing areas under two or more correlated reciever operating characteristics curves: a nonparamentric approach. Biometrics 1988, 44:837-845.
14. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
15. Zurbig P., Renfrow M.B., Schiffer E., Novak J., Walden M., Wittke S., et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27:2111-2125.
16. Roncalli J., Smih F., Desmoulin F., Dumonteil N., Harmancey R., Hennig S., et al. NMR and cDNA array analysis prior to heart failure reveals an increase of unsaturated lipids, a glutamine/glutamate ratio decrease and a specific transcriptome adaptation in obese rat heart. J Mol Cell Cardiol 2007, 42:526-539.
17. Harmancey R., Senard J.M., Rouet P., Pathak A., Smih F. Adrenomedullin inhibits adipogenesis under transcriptional control of insulin. Diabetes 2007, 56:553-563.
18. Ren J. Short-term administration of insulin-like growth factor I (IGF-1) does not induce myocardial IGF-1 resistance. Growth Horm IGF Res 2002, 12:162-168.
19. Terrien X., Bonvin E., Corroyer S., Tabary O., Clement A., Henrion Caude A. Intracellular colocalization and interaction of IGF-binding protein-2 with the cyclin-dependent kinase inhibitor p21CIP1/WAF1 during growth inhibition. Biochem J 2005, 392:457-465.
20. Wheatcroft S.B., Kearney M.T. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009, 20:153-162.
21. Fuller S.J., Mynett J.R., Sugden P.H. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J 1992, 282(Pt 1):85-90.
22. Shimasaki S., Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res 1991, 3:243-266.
23. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
24. Osterziel K.J., Ranke M.B., Strohm O., Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol (Oxf) 2000, 53:61-68.
25. Duerr R.L., Huang S., Miraliakbar H.R., Clark R., Chien K.R., Ross J. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995, 95:619-627.
26. Donath M.Y., Sutsch G., Yan X.W., Piva B., Brunner H.P., Glatz Y., et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998, 83:3177-3183.
27. Cittadini A., Grossman J.D., Napoli R., Katz S.E., Stromer H., Smith R.J., et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997, 29:1109-1116.
28. Isgaard J., Kujacic V., Jennische E., Holmang A., Sun X.Y., Hedner T., et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997, 27:517-525.
29. Sharples A.P., Al-Shanti N., Hughes D.C., Lewis M.P., Stewart C.E. The role of insulin-like-growth factor binding protein 2 (IGFBP2) and phosphatase and tensin homologue (PTEN) in the regulation of myoblast differentiation and hypertrophy. Growth Horm IGF Res 2013, 23:53-61.
30. Wu C., Macleod I., Su A.I. BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res 2013, 41:D561-D565.
31. Rehfeldt C., Renne U., Sawitzky M., Binder G., Hoeflich A. Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2. Am J Physiol Endocrinol Metab 2010, 299:E287-E298.